Search

Your search keyword '"Renal cell carcinoma -- Physiological aspects"' showing total 7 results
Start Over Descriptor "Renal cell carcinoma -- Physiological aspects" Journal plus company updates

Refine your results

7 results on '"Renal cell carcinoma -- Physiological aspects"'

1. Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Subjects
Bristol-Myers Squibb Co., Cancer treatment -- Physiological aspects, Biotechnology industries -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, General interest, News, opinion and commentary, Opdivo (Medication)
Abstract

San Francisco: Calithera Biosciences, Inc. has issued the following press release: Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing [...]

Published
2017

2. Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Subjects
Bristol-Myers Squibb Co., Cancer treatment -- Physiological aspects, Biotechnology industries -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, General interest, News, opinion and commentary, Opdivo (Medication)
Abstract

San Francisco: Calithera Biosciences, Inc. has issued the following press release: Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing [...]

Published
2017

3. Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Subjects
Bristol-Myers Squibb Co., Cancer treatment -- Physiological aspects, Biotechnology industries -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, General interest, News, opinion and commentary, Opdivo (Medication)
Abstract

San Francisco: Calithera Biosciences, Inc. has issued the following press release: Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing [...]

Published
2017

4. Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Subjects
Bristol-Myers Squibb Co., Cancer treatment -- Physiological aspects, Biotechnology industries -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, General interest, News, opinion and commentary, Opdivo (Medication)
Abstract

San Francisco: Calithera Biosciences, Inc. has issued the following press release: Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing [...]

Published
2016

5. Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Subjects
Bristol-Myers Squibb Co., Cancer treatment -- Physiological aspects, Biotechnology industries -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, General interest, News, opinion and commentary, Opdivo (Medication)
Abstract

San Francisco: Calithera Biosciences, Inc. has issued the following press release: Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing [...]

Published
2016

6. Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Subjects
Bristol-Myers Squibb Co., Cancer treatment -- Physiological aspects, Biotechnology industries -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, General interest, News, opinion and commentary, Opdivo (Medication)
Abstract

San Francisco: Calithera Biosciences, Inc. has issued the following press release: Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing [...]

Published
2016

7. Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Subjects
Bristol-Myers Squibb Co., Cancer treatment -- Physiological aspects, Medical research -- Physiological aspects, Biotechnology industries -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, General interest, News, opinion and commentary, Opdivo (Medication)
Abstract

New York: Bristol-Myers Squibb Company has issued the following news release -Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing [...]

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results